REG
MAR
PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES
PILA PHARMA AB (publ) (FN STO: PILA) today informs the continuation of preparations for the clinical trial application for PP-CT03, a pivotal and pioneering 12-week Phase 2a stud...
REG
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025
PILA PHARMA AB (publ) höll på torsdagen den 29 april 2025 årsstämma hos MAQS Advokatbyrå, Gibraltargatan 7 i Malmö. Följande huvudsakliga beslut fattades:Fastställande av resulta...
PILA PHARMA UPCOMING INVESTOR MEETINGS
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites investors and others with interest in the Company, to meet PILA PHARMA at these upcoming events:
Malmömorgon (Slagthuset, Mal...
PILA PHARMA: REMINDER - LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING
PILA PHARMA AB (publ) (FN STO: PILA) today reminds shareholders that today, 23 April is the last day to register attendance at this year's Annual General meeting.
PILA PHARMA wel...
REG
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdag den 29 april 2025, kl. 15.00 i MAQS Advokatbyrås loka...
REG
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024
PILA PHARMA AB (publ) (FN STO: PILA) announces that the annual report (in Swedish) is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-informa...
REG
PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY - 31 DECEMBER 2024)
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2024.
The report can be found on the Company's website: https...
PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites interested investors to participate in our scheduled H2 Report event in the coming week:
___________Stokk.io Online Webinar -...
REG
MAR
PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (t...
PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO)
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the appointment of Hampus Darrell as new CFO.
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Researc...
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") (FN STO: PILA) hereby invites you to participate in these upcoming Nordic investor events:
PILA PHARMA AB Chairman & CEO increase their holdings
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), (FN STO: PILA), today announces that Chairman of the Board, Dorte X. Gram and CEO Gustav H. Gram have purchased additional...
PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN"
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to view and/or listen to the broadcast from todays episode of "Millionærklubben" (Millionaire's Club) where PILA PHARMA's...
REG
MAR
PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN
PILA PHARMA AB (publ) (FN STO:PILA) today announces the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical tria...
REG
MAR
PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsal...
REG
MAR
PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN
PILA PHARMA AB (publ) (FN STO:PILA) today announces it has chosen to alter the operational plan for its next clinical trial, PP-CT03, a phase 2a safety and tolerability trial in...
CEO Gustav H. Gram increases holding in PILA PHARMA AB
Pila Pharma AB (publ) (FN STO: PILA) announces that recently appointed CEO Gustav H. Gram has purchased additional shares. The purchases occurred on Wednesday, 30 August, where 2...
Om PILA PHARMA
Webbplats
pilapharma.com
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs ()
Förändring ()